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A B S T R A C T
Purpose
To assess the impact of age on outcome and to analyze the projected years of life lost in patients
with multiple myeloma.
Patients and Methods
Ten thousand five hundred forty-nine patients were evaluated; 6,996 patients were treated with
conventional chemotherapy, and 3,553 patients were treated with high-dose therapy with autologous
stem-cell transplantation.
Results
Mean observed and relative overall survival times in the entire cohort were 3.7 and 3.9 years,
respectively. Observed survival decreased steadily from 6.4 years in patients younger than age
50 years to 2.5 years in patients  age 80 years. A similar decrease was noted for relative
survival. Higher age correlated significantly with higher International Staging System (ISS)
stage. Relative excess risk of death differed significantly between 10-year age cohorts
beginning from age 40 years (P  .001 for age 50 to 59 v age 40 to 49, P  .001 for age 60
to 69 v age 50 to 59, P  .001 for age 70 to 79 v age 60 to 69, and P  .009 for age  80 v
70 to 79). The average years of life lost per patient was 16.8 years in the entire patient cohort
and decreased steadily from 36.1 years in patients younger than 40 years old to 4.6 years in
patients  age 80 years.
Conclusion
Age is associated with higher ISS stage and is an important risk factor for early mortality. Survival
declined continuously by each decade from age 50 to age  80 from more than 6 to less than 3
years. The average of years of life lost in patients with myeloma is higher than in many other
cancers and amounts to more than 30 years in patients younger than 40 years old but decreases
to less than 5 years in patients age 80 years or older.
J Clin Oncol 28:1599-1605. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Multiple myeloma (MM) accounts for 1.4% of all
cancers and for1.9%ofall cancermortality,1 and the
numberofnewcasesperyear is19,920 in theUnited
States1 and 28,700 in the European Union.2 MM
is a disease of the elderly population, with a me-
dian age at manifestation of approximately 70
years in the United States3 and 72 years in Eu-
rope.4 Median survival times are 5 to 7 years in
patients treated with high-dose chemotherapy
and autologous transplantation and 3 to 4 years in
patients treated with conventional chemothera-
py.5 Themajority of patients treatedwith high-dose
therapy andautologous transplantation are younger
than65 years old,whereas patients treatedwith con-
ventional therapy are usually older than age 65.
Although survival tends to be longer in younger
patients,5-7 accurate data on the outcome inpatients
of different age categories have not been reported. A
further important issue regarding information on
the projected years of life lost in patients of different
age cohorts at diagnosis has not been systematically
addressed so far. Estimation of years of life lost pro-
vides amore accurate depiction of premature death
by weighing deaths occurring at younger ages more
heavily than those occurring in older patients and
thus functions as an additional tool for quantifying
the burden ofMM.Here, we report results obtained
in a large group of patients with MM treated either
with conventional or high-dose therapy.
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PATIENTS AND METHODS
Data from10,549patientswere submitted from17 institutionsor studygroups
in North America, Europe, and Japan. Patients were enrolled between 1982
and 2002. Six thousand nine hundred ninety-six patients received conven-
tional chemotherapy as first-line treatment, and 3,553 patients were subjected
to high-dose therapy with planned autologous stem cell transplantation. The
median age of patients enrolled onto clinical trials was 60 years, and the
median age of other patients was 63 years. Median follow-up time was 3.25
years (maximum, 19.21 years). Patient characteristics are listed in Table 1.
The relationship between prognostic factors and age was assessed using
Spearman rank correlation coefficient.8 A maximum likelihood model was
used to estimate relative excess risk (RER) for death in patients in different age
cohorts using a generalized linear model approach with Poisson error struc-
ture using exact survival times and collapsed data, as described byDickman et
al.9 Estimates of relative overall survival within age groups were determined
using the Kaplan-Meier method10 and were compared using the log-rank
test,11 while taking the normal mortality expectations of respective popula-
tions adjusted for age, sex, year of diagnosis, and nationality into account.
Life-tables of estimated population mortality rates for the country of each
treating institution were obtained from the Human Mortality Database.12
Years of life lost were computed by subtracting the actual survival time of
individualpatients sincediagnosis fromthepatient’s life expectancyat the time
of diagnosis based on life-tables from the country of origin. The value of the
economic loss as a result of premature deaths was estimated using the
willingness-to-pay approach multiplying the years of life lost by a previously
published value of a year of life of $150,000.13
RESULTS
Patient characteristics are listed in Table 1. More than half of the
patients (57.5%) had been enrolled by European study groups or
institutions, and 33.2% came from North American and 9.3% from
Asian institutions and trials. The majority of patients (70.3%) had
been enrolled onto clinical trials, and 84% were 50 years of age or
older. 2 tests for differences by regions in clinical trials or age were
significant at P .001. The distribution of prognostic factors by age
category revealed a significant correlation between higher age and
more advanced International Staging System (ISS) stage (r  0.13;
95% CI, 0.11 to 0.16) and between age and the parameters that ac-
count for ISS stage, namely2-microglobulin (r 0.16; 95%CI, 0.14
to 0.19) and albumin (r0.11; 95%CI,0.13 to0.09; Table 2).
Lactate dehydrogenase and bone marrow plasma cell infiltration as
factors reflecting the biology of myeloma were evenly distributed
between all age categories (r  0.03; 95% CI, 0.06 to 0.00; and
r 0.00; 95% CI,0.02 to 0.02, respectively). Median observed and
relative survival times in the entire cohort were 3.7 and 3.9 years,
respectively, anddidnotdiffer significantly betweenmenandwomen.
The median relative survival time decreased steadily in the different
age categories from 5.2 years in patients younger than 50 years old to
4.6 years inpatients age 50 to 59 years, 3.6 years inpatients age 60 to 69
years, 3.1 years in patients age 70 to 79 years, and 2.6 years in patients
age 80 years (Fig 1A); the correspondingmedian observed survival
times were 6.4, 5.3, 4.3, 3.4, and 2.5 years, respectively (Fig 1B). In
patients age 40 to 49, 50 to 59, and 60 to 69 years, median observed
survival times were 5.7, 4.7, and 4.0 years, respectively, in patients
treated with conventional chemotherapy and 8.0, 6.7, and 6.2 years,
respectively, in patients treated with high-dose chemotherapy and
autologous stem-cell transplantation (Figs 1C and 1D).
RER of death was similar between patients age less than 40 years
and patients age 40 to 49 (RER  1.034, P  .692) but differed
significantly between all of the other 10-year age categories, with the
younger cohort always showing reduced risk of death (age 50 to 59 v
age 40 to 49: RER  1.201, P  .001; age 60 to 69 v age 50 to 59:
RER  1.288, P  .001; age 60 to 69 v age 70 to 79: RER  1.190,
P .001; age 80 v age 70 to 79: RER 1.278, P .009; Table 3).
Similar findings were obtained when RER was analyzed by age cate-
gory separately in men, women, and patients treated with standard
therapy. In patients with autologous transplantation, RERwas signif-
icantly increased in the age category of 60 to 69 years versus 50 to 59
years (RER 1.263, P .0058) but not significantly higher in the age
category of 70 to 79 years versus 60 to 69 years (RER  1.130,
P .7463). Increased RER estimates for each age group compared
with the adjacent age group indicate a trend toward progressively
higher risk of death with increasing age, even after adjustment for
expected mortality.
Table 1. Patient Demographics and Clinical Characteristics
Characteristic
No. of Patients
(N  10,549) %
Age at start of therapy, years
Median 60
Range 20-93
 40 312 3.0
40-49 1,377 13.0
50-59 3,221 30.5
60-69 3,603 34.2
70-79 1,744 16.5
 80 292 2.8
Sex
Male 5,253 49.8
Female 5,296 50.2
M component
IgG 5,777 60.0
IgA 2,327 24.2
Light chain only 1,021 10.6
IgD 294 3.0
Biclonal 8 0.1
Other 202 2.1
Missing 920 —
ISS stage
I 2,282 28.4
II 3,113 38.7
III 2,648 32.9
Missing 2,506 —
Geographic region
Asia† 983 9.3
North America 3,499 33.2
Europe 6,067 57.5
Patients in clinical trials by region
Asia† 983 100
Europe 4,864 80.2
North America 2,549 72.9
Age  50 years by region
Asia† 920 93.6
North America 3,009 86.0
Europe 4,931 81.3
Abbreviations: Ig, immunoglobulin; ISS, International Staging System.
Percentages are calculated from nonmissing values.
†Includes Japan only.
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In the entire group of patients, the average years of life lost per
patient was 16.8 years. The average of years of life lost was highest in
patients younger than age 40 years (36.1 years) and decreased steadily
(Fig 1B) in patients age 40 to 49, 50 to 59, 60 to 69, 70 to 79, and 80
(26.9, 19.9, 13.7, 8.1, and 4.6 years, respectively; Table 4). Similar
figures with some variations were observed for men and women
(Table 4) and for patients treated with standard or high-dose chemo-
therapy (Table 5). Average years of life lost in patients treated with
conventional therapy seemed to be approximately 2 years greater in
the age cohorts between 40 and 59 years but 2 years less in patients
 age 70 compared with patients treated with high-dose therapy
(Table 5).
For all 10,549 patients included in this analysis, the total number
of potential years of life lost amounted to 177,306 years (Table 4).
Using a standard value of a year of life formen and women of all ages
(ie, $150,000), the value of life-years lost in a myeloma patient diag-
nosed at age 50 amounts to $4,035,000, and the value of life-years
lost in the entire study population equals $26,595,900,000.
DISCUSSION
This study documents the significant age dependency of survival in
MM.Meanobserved survivalwas3.7 years in the entire cohort and6.3
years in patients age less than 50 years. Mean observed survival de-
creased steadily and significantly with each age decade to 2.5 years in
patients age 80 years. This correlation is remarkable and probably
not a result of an increasingly more aggressive phenotype of the my-
eloma clone because typical risk factors for a more rapid tumor pro-
gression, such as lactate dehydrogenase or bonemarrowmyeloma cell
infiltration, didnot varybetweenpatients of different age cohorts.The
majority of previous studies were also unable to find significant im-
balances of cytogenetic risk factors between older and younger pa-
tients,14,15 and in a small subgroup of 385 patients enrolled onto this
study, no correlations between the proportion cytogenetic risk factors
and age were observed (data not shown). However, we found a re-
markable correlation between older age andmore advanced ISS stage;
41% of patients younger than 40 years of age presented with ISS stage
I, but only 12% of patients age 80 years presented with ISS stage I.
ISS stage is defined by 2-microglobulin and albumin, both of which
correlatedwith age, with2-microglobulin beingmore closely associ-
ated.2-Microglobulin is an important constituent of theHLA class I
surface molecule,16 which presents intracellularly processed antigens
to CD8 T lymphocytes. 2-Microglobulin serum levels have been
found to correlate with age,17 renal function,18 and survival in a series
of diseases such as chronic lymphocytic leukemia,19 Hodgkin’s dis-
ease,20 non-Hodgkin’s lymphoma,21 andchronicmyelogenous leuke-
mia.22 Our results show that2-microglobulin levels do not correlate
with bone marrowmyeloma cell infiltration and thus do not directly
reflect the tumor mass. Because higher 2-microglobulin levels pre-
dict poorer outcome in patients with similar stage and age, increased
levelsmaymirror thehost’s attempt toovercomean insufficientT-cell
response against the tumor. This phenomenon seems to accelerate
with increasing age and is likely to contribute to poorer outcome in
elderly patients. It may also explain, in part, why overall survival has
not been improved in the elderly population of myeloma patients
after the introduction of immunostimulatory drugs like thalido-
mide and lenalidomide.23
Our study revealed an average of 16.8 years of life lost per patient
in the entire cohort of 10,549 myeloma patients enrolled onto this
study. This is significantly higher than the 12.5 years reported for all
cancers combined24 andgreater thanpreviously reported forMM.For
2004, the USNational Center of Health Statistics reported an average
of 14.0 years of life lost for patients withmyeloma, with amedian age
at diagnosis of 70 years.25 In 2007, the British Columbia Cancer Reg-
istry reported an average of 12.7 years of life lost as a result of
myeloma, whereas for the East Anglia region in the United King-
dom, an average of 10.3 years of life lost was calculated for patients
with MM using data obtained between 1990 and 1994.24 The main
Table 2. Prognostic Factors of Patients According to Age Group
Factor
Age Group
Spearman’s
Correlation
Coefficient 95% CI
 40 Years 40-49 Years 50-59 Years 60-69 Years 70-79 Years  80 Years
No. of
Patients/Total
No. %
No. of
Patients/Total
No. %
No. of
Patients/Total
No. %
No. of
Patients/Total
No. %
No. of
Patients/Total
No. %
No. of
Patients/Total
No. %
B2M  3.5 g/mL 106/238 45 507/1,139 45 1,354/2,622 52 1,723/2,882 60 922/1,366 67 142/191 74 0.16 0.14 to 0.19
Albumin  3.5 g/dL 80/251 32 378/1,145 33 1,044/2,758 38 1,325/3,224 41 757/1,651 46 150/279 54 0.11 0.13 to 0.09
HgB  10 g/dL 114/294 39 482/1,320 37 1,186/3,103 38 1,409/3,459 41 724/1,689 43 146/288 51 0.08 0.10 to 0.06
Creatinine  2 mg/dL 51/287 18 189/1,307 14 502/3,107 16 582/3,480 17 341/1,702 20 59/284 21 0.07 0.05 to 0.09
Platelets  130 
103/L 36/247 15 116/1,173 10 312/2,832 11 432/3,359 13 199/1,690 12 41/287 14 0.04 0.06 to 0.02
Calcium  10 mg/dL 88/256 34 393/1,189 33 999/2,867 35 1,076/3,201 34 501/1,545 32 76/257 30 0.02 0.04 to 0.00
CRP  0.8 mg/dL 27/117 23 142/578 25 412/1,431 29 444/1,477 30 205/704 29 38/128 30 0.06 0.03 to 0.09
BMPC  33% 165/279 59 727/1,265 57 1,741/2,984 58 1,990/3,336 60 986/1,652 60 160/278 58 0.00 0.02 to 0.02
LDH  normal 30/95 32 128/505 25 337/1,307 26 369/1,343 27 156/603 26 26/112 23 0.03 0.06 to 0.00
ISS stage 0.13 0.11 to 0.16
I 89/219 41 403/1,048 38 785/2,456 32 709/2,783 25 274/1,350 20 22/187 12
II 63/219 29 375/1,048 36 929/2,456 38 1,115/2,783 40 549/1,350 41 82/187 44
III 67/219 31 270/1,048 26 742/2,456 30 959/2,783 34 527/1,350 39 83/187 44
Abbreviations: B2M, 2-microglobulin; HgB, hemoglobin; CRP, C-reactive protein; BMPC, bone marrow plasma cells; LDH, lactate dehydrogenase.
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reason for this discrepancy can be ascribed to the lower age of our
patients (median age, 60 years), 70%ofwhomhadbeen enrolled onto
clinical studies and 30% of whom were referred for treatment to
specialized myeloma centers5; in the routine clinical setting, patients
are seen at a median age of diagnosis of 70 to 72 years.
This analysis shows the strong dependency of the potential
loss of years of life on the age at diagnosis of the disease. The
average number of years of life lost decreased more than nine-fold
from36.1years inpatientsdiagnosedbefore age40years to4.6 years in
patients age 80 years. Another interesting observation is the lesser
loss of years of life in thepatients age 40 to49and50 to59years treated
with high-dose chemotherapy and autologous stem-cell transplanta-
tion (25.6 and 18.2 years, respectively) compared with conventional
therapy (27.4 and 21.0 years, respectively); however, this comparison
is limited by the retrospective and nonrandomized nature. Still, this
finding corresponds with the notion that the greatest benefit of high-
dose therapy and autologous transplantation is derived in patients
between 40 and 59 years of age,26 whereas in patients older or younger
than this age range, the impactonoverall survivalof this therapy seems
less pronounced.
The total number of estimated years of life lost in our patient
cohort is 177,306 years, a figure that is slightly higher than the esti-
mated 151,100 years of life lost for the 10,670 US patients with my-
eloma who died in the year 2004.3 This higher number is probably a
reflection of the younger age of the patients in this analysis.
Some limitations to the present study warrant mention. First,
patients analyzed in this study were enrolled over a long period (1982
to 2002). We previously showed that in patients started on conven-
tional therapy, survival increased significantly in patients enrolled
between 1998 and 2002 compared with patients entered earlier.5 This
did not apply to patients treated with high-dose chemotherapy fol-
lowed by autologous transplantation. Although the improvement in
survival in patients enrolled during the last period seems to be partly a
resultof the introductionofnoveldrugs, other factors, suchas ahigher
proportion of patients receiving a transplantation at relapse, better
supportive care, and a shift in prognostic factors with more patients
presentingwithmore favorable risk factors than previously,may have
contributed to the slightly but significantly longer survival.5 The
longer survival expected with the newly available drugs and the other
changes mentioned should markedly reduce the years of life lost of
younger patients in the future. Second, forecasting life expectancy by
extrapolating from the past does not account for possible new, life-
prolonging treatments andmay thusunderestimate the futuregains in
survival, limiting the precision of present estimates. Third, there was
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Fig 1. (A) Relative overall survival and (B) observed and expected overall survival in patients according to age at diagnosis. (C) Observed and expected survival in
patients treated with conventional chemotherapy according to age at diagnosis. (D) Observed and expected survival in patients treated with high-dose chemotherapy
according to age at diagnosis. Solid lines represent observed survival, and dashed lines represent expected survival.
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significant heterogeneity in the age distribution and inclusion of pa-
tients in clinical trials. Patients from Asia were older than those from
NorthAmerica andEurope.All of theAsianpatients hadbeen studied
within clinical trials, whereas 80.2%of the European and72.3%of the
North American patients participated in clinical studies. Fourth, the
patients included in this analysis, particularly the elderly cohort, were
likely in better condition than the general population of myeloma
patients that are not entered onto clinical studies because of multi-
morbidity and/or severe myeloma-related complications such as
marked renal impairment or severely suppressed hematopoiesis.
Hence, the influence of age might even be greater in a population-
based study. Finally, several approaches can be used to estimate the
economic burden of mortality. We applied the willingness-to-pay
approach that incorporates both lost productivity as a result of death
and the intrinsic value of life by estimating the amount an average
individual would be willing to pay for an additional year of life.27 We
used the commonly used value of $150,000 for a year of life, which is
based on prior research13 on the willingness to pay for an additional
year of life.Othermethods, such as thehumancapital approach,28 put
moreemphasisonsex-andage-specificaverageearningsandcombine
these values with expected productivity trends and years of life lost
to earnings.
Using a standard value of life13,29 formen and women of all ages
(ie, $150,000) the value of life lost for ourmyeloma patients amounts
to $26,595,900,000. Although this figure shows the substantial eco-
nomic loss of myeloma for the society, the personal loss experienced
by the people close to the patient is usually enormous and cannot be
measured in financial terms.
In conclusion, age is associated with higher ISS stage and is an
important risk factor for early mortality inMM. In addition, survival
declines continuously by each decade from age 50 to age 80 years,
even after adjustment for expectedmortality. Because of the still rela-
tively short survivalofpatientswithmyeloma, the loss inyearsof life in
patientswithmanifestationbeforeage40 is greatest andamounts to36
years, whereas in patients diagnosed at age 80, the average loss of
years of life is approximately 4 to 5 years. Widespread use of the
novel drugs thalidomide, bortezomib, and lenalidomide is likely to
reduce the loss of precious life time but will not transform myeloma
into a chronic disease with a life expectancy similar to that of the
healthy population. Better understandingof the underlyingprocess of
malignant transformation and tumor propagation ultimately should
Table 3. Relative Excess Risk of Death in Various Patient Subgroups
Subgroup and Age
Category RER 95% CI P
Age, years
 40 v 40-49 1.03 0.88 to 1.22 .692
40-49 v 50-59 1.20 1.10 to 1.31  .001
50-59 v 60-69 1.29 1.21 to 1.37  .001
60-69 v 70-79 1.19 1.10 to 1.28  .001
70-79 v 80 1.28 1.07 to 1.52 .009
Males
 40 v 40-49 1.02 0.84 to 1.26 .818
40-49 v 50-59 1.25 1.11 to 1.40  .001
50-59 v 60-69 1.30 1.20 to 1.42  .001
60-69 v 70-79 1.21 1.09 to 1.35  .001
70-79 v 80 1.31 0.99 to 1.72 .068
Females
 40 v 40-49 1.05 0.79 to 1.38 .757
40-49 v 50-59 1.14 0.99 to 1.31 .051
50-59 v 60-69 1.27 1.15 to 1.41  .001
60-69 v 70-79 1.18 1.05 to 1.32 .005
70-79 v 80 1.28 1.02 to 1.61 .046
Conventional chemotherapy
 40 v 40-49 1.09 0.90 to 1.32 .359
40-49 v 50-59 1.22 1.11 to 1.35  .001
50-59 v 60-69 1.16 1.08 to 1.25  .001
60-69 v 70-79 1.11 1.02 to 1.20 .012
70-79 v 80 1.27 1.07 to 1.52 .010
High-dose therapy
 40 v 40-49 0.93 0.37 to 1.30 .685
40-49 v 50-59 1.10 0.92 to 1.31 .282
50-59 v 60-69 1.26 1.07 to 1.49 .006
60-69 v 70-79 1.13 0.55 to 2.33 .746
70-79 v 80 — — —
Abbreviation: RER, relative excess risk.
Table 4. Mean Years of Expected and Observed Survival and Years of Life Lost for Men and Women
Outcome
Age at Diagnosis
Total Average 40 Years 40 to 49 Years 50 to 59 Years 60 to 69 Years 70 to 79 Years  80 Years
Total patients 312 1,377 3,221 3,603 1,744 292 10,549
Men 208 562 1,900 1,536 927 120 5,253
Women 104 815 1,321 2,067 817 172 5,296
Mean expected survival, years 42.4 33.3 25.2 17.9 11.5 7.1 21.51
Men 40.5 36.3 23.3 20.3 10.2 6.1 21.79
Women 46.1 31.2 28.0 16.2 12.9 7.7 21.25
Mean observed survival, years 6.3 6.4 5.3 4.3 3.4 2.5 4.74
Men 6.0 6.2 5.1 4.1 3.2 2.2 4.56
Women 6.5 6.5 5.4 4.5 3.7 2.6 4.89
Average years of life lost per patient 36.1 26.9 19.9 13.7 8.1 4.6 16.8
Men 34.5 30.1 18.2 16.3 7.0 3.9 17.26
Women 39.7 24.7 22.6 11.6 9.2 5.1 16.33
Potential years of life lost 11,250.9 37,088.4 64,249.8 49,298.4 14,074.9 1,343.6 177,306.0
Men 7,185.7 16,939.4 34,500.7 24,963.0 6,522.6 464.7 90,576.1
Women 4,126.1 20,152.1 29,920.2 24,068.9 7,540.4 879.2 86,686.9
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enable the development ofmore efficient therapy and better outcome
of patients afflicted with this still difficult to treat disease.
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